Characterization of Escherichia coli isolates potentially covered by ExPEC4V and ExPEC10V, that were collected from post-transrectal ultrasound-guided prostate needle biopsy invasive urinary tract and bloodstream infections

Vaccine. 2020 Jul 14;38(33):5100-5104. doi: 10.1016/j.vaccine.2020.06.024. Epub 2020 Jun 16.

Abstract

There is an increasing incidence of infectious complications caused by extraintestinal pathogenic Escherichia coli (ExPEC) after transrectal ultrasound-guided prostate needle biopsy (TRUS-PNB), and a need for prophylaxis methods effective against associated antibiotic-resistant organisms. We aimed to identify the O-serotypes of ExPEC isolates collected in a sample of 60 patients with invasive ExPEC disease (IED) after TRUS-PNB, by serotype-specific agglutination and polymerase chain reaction (PCR) assays. The prevalence of O-serotypes included in a tetravalent ExPEC vaccine was 38.3% by agglutination and 46.7% by PCR, while the prevalence of O-serotypes included in a decavalent vaccine was 58.3% and 73.3%, respectively. Therefore, compared to the tetravalent vaccine, the decavalent vaccine would theoretically provide coverage for serotypes carried by a higher proportion of circulating ExPEC in patients undergoing TRUS-PNB, including a high proportion of antibiotic-resistant organisms.

Keywords: Antimicrobial resistance; Extraintestinal Pathogenic Escherichia coli; Serotyping.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biopsy, Needle
  • Escherichia coli
  • Escherichia coli Infections*
  • Humans
  • Male
  • Prostate / diagnostic imaging
  • Sepsis*
  • Ultrasonography, Interventional
  • Urinary Tract Infections*
  • Urinary Tract*